prostratin has been researched along with vorinostat in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, S; Lu, D; Qu, X; Wang, P; Ying, H; Zhang, Y; Zhou, X; Zhu, H | 1 |
| Al-Jabri, AA | 1 |
| Ayyavoo, V; Bar-Joseph, Z; Chattopadhyay, A; Jain, S; Mancini, AE; Sluis-Cremer, N; Venkatachari, NJ; Zerbato, JM | 1 |
| Bohn-Wippert, K; Dar, RD; Megaridis, MR; Tevonian, EN | 1 |
| Gohda, J; Inoue, JI; Ishida, T; Kawaguchi, Y; Liu, K; Suzuki, K; Takeuchi, H; Xie, X | 1 |
| Andersen, RJ; Ntie-Kang, F; Tietjen, I | 1 |
| Alcami, J; Bedoya, LM; Beltrán, M; Bueno, P; Cachet, X; Camarero, S; De la Torre-Tarazona, HE; Fernández-García, JL; Jiménez, R; Litaudon, M; Nothias, LF; Paolini, J; Román, L | 1 |
1 review(s) available for prostratin and vorinostat
| Article | Year |
|---|---|
Natural product-derived compounds in HIV suppression, remission, and eradication strategies.
Topics: Anti-HIV Agents; Biological Products; Bryostatins; Depsipeptides; Disease Reservoirs; Diterpenes; Drug Discovery; Gene Products, tat; Histone Deacetylase Inhibitors; HIV Infections; HIV-1; Humans; Phorbol Esters; rev Gene Products, Human Immunodeficiency Virus; Virus Latency; Vorinostat | 2018 |
6 other study(ies) available for prostratin and vorinostat
| Article | Year |
|---|---|
Selective histonedeacetylase inhibitor M344 intervenes in HIV-1 latency through increasing histone acetylation and activation of NF-kappaB.
Topics: Acetylation; Active Transport, Cell Nucleus; Blotting, Western; Chromatin Immunoprecipitation; DNA Primers; Drug Synergism; Flow Cytometry; Gene Expression Regulation, Viral; Green Fluorescent Proteins; HEK293 Cells; Histone Deacetylase Inhibitors; Histones; HIV Long Terminal Repeat; HIV-1; Humans; Hydroxamic Acids; Immunohistochemistry; Jurkat Cells; Microscopy, Fluorescence; NF-kappa B; Phorbol Esters; Propidium; Virus Latency; Vorinostat | 2012 |
Forcing the enemy to come out and surrender: a strategy for an AIDS cure.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Depsipeptides; Enzyme Activation; Histone Deacetylase Inhibitors; HIV-1; Humans; Hydroxamic Acids; Immune Evasion; NF-kappa B; Phorbol Esters; Protein Kinase C; Virus Latency; Vorinostat | 2015 |
Temporal transcriptional response to latency reversing agents identifies specific factors regulating HIV-1 viral transcriptional switch.
Topics: CD4-Positive T-Lymphocytes; Gene Expression Profiling; Gene Expression Regulation, Viral; HIV-1; Humans; Hydroxamic Acids; Jurkat Cells; Male; Phorbol Esters; Signal Transduction; Systems Biology; Tumor Necrosis Factor-alpha; Virus Activation; Virus Latency; Vorinostat | 2015 |
Similarity in viral and host promoters couples viral reactivation with host cell migration.
Topics: CD4-Positive T-Lymphocytes; Cell Movement; Depsipeptides; Gene Expression Regulation; HIV Long Terminal Repeat; HIV-1; HL-60 Cells; Host-Pathogen Interactions; Humans; Hydroxamic Acids; Indoles; Ionomycin; Jurkat Cells; Panobinostat; Phorbol Esters; Primary Cell Culture; Promoter Regions, Genetic; Receptors, CXCR4; Tamoxifen; tat Gene Products, Human Immunodeficiency Virus; Transcription, Genetic; Tumor Necrosis Factor-alpha; Virus Activation; Virus Latency; Vorinostat | 2017 |
BI-2536 and BI-6727, dual Polo-like kinase/bromodomain inhibitors, effectively reactivate latent HIV-1.
Topics: Cell Line, Tumor; Drug Combinations; Gene Expression Regulation, Viral; Histone Deacetylase Inhibitors; HIV-1; Host-Pathogen Interactions; Humans; Inhibitory Concentration 50; Leukocytes, Mononuclear; Lymphocytes; Monocytes; Phorbol Esters; Primary Cell Culture; Protein Domains; Protein Kinase Inhibitors; Pteridines; RNA, Messenger; RNA, Viral; THP-1 Cells; Transcription, Genetic; Virus Activation; Virus Latency; Vorinostat | 2018 |
4-Deoxyphorbol inhibits HIV-1 infection in synergism with antiretroviral drugs and reactivates viral reservoirs through PKC/MEK activation synergizing with vorinostat.
Topics: Anti-HIV Agents; Bryostatins; CD4-Positive T-Lymphocytes; Cell Survival; Drug Synergism; HIV Infections; HIV-1; Humans; Jurkat Cells; Mitogen-Activated Protein Kinase Kinases; Phorbol Esters; Protein Kinase C; Signal Transduction; Virus Activation; Virus Latency; Vorinostat | 2020 |